Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives $29.25 Average Price Target from Analysts

Shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) have been given a consensus rating of “Buy” by the seven analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, four have given a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $29.25.

EYPT has been the topic of a number of research analyst reports. Royal Bank Of Canada lifted their price target on shares of Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. TD Cowen upgraded shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a research report on Friday, December 19th. Mizuho set a $28.00 target price on shares of Eyepoint Pharmaceuticals in a research note on Monday, October 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Thursday. Finally, Cantor Fitzgerald upgraded Eyepoint Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, November 25th.

Eyepoint Pharmaceuticals Trading Up 1.8%

NASDAQ EYPT opened at $15.45 on Thursday. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of -5.17 and a beta of 1.63. Eyepoint Pharmaceuticals has a twelve month low of $3.91 and a twelve month high of $19.11. The stock has a 50-day moving average of $16.26 and a 200 day moving average of $13.45.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.08). The business had revenue of $0.97 million during the quarter, compared to analyst estimates of $3.33 million. Eyepoint Pharmaceuticals had a negative net margin of 485.95% and a negative return on equity of 76.13%. Equities analysts predict that Eyepoint Pharmaceuticals will post -2.13 EPS for the current fiscal year.

Insider Activity at Eyepoint Pharmaceuticals

In related news, insider Ramiro Ribeiro sold 42,544 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $17.10, for a total transaction of $727,502.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.46% of the company’s stock.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC raised its position in shares of Eyepoint Pharmaceuticals by 1,636.5% in the second quarter. Nisa Investment Advisors LLC now owns 2,900 shares of the company’s stock valued at $27,000 after buying an additional 2,733 shares during the last quarter. State of Alaska Department of Revenue purchased a new stake in Eyepoint Pharmaceuticals during the 3rd quarter valued at about $50,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Eyepoint Pharmaceuticals by 51.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock valued at $74,000 after acquiring an additional 1,358 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in Eyepoint Pharmaceuticals in the 3rd quarter worth approximately $76,000. Finally, Tower Research Capital LLC TRC lifted its stake in Eyepoint Pharmaceuticals by 218.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock worth $82,000 after purchasing an additional 5,967 shares in the last quarter. Institutional investors and hedge funds own 99.41% of the company’s stock.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.